Drugs / EB-DUO-CAR-NK-CEA/GCC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07589517 | Feb 2026 → Mar 2027 expected | colorectal adenocarcinoma | Beijing Biotech | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EB-DUO-CAR-NK-CEA/GCC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07589517 ↗ |
| Route | Other | “infusion of the assigned dual-target CAR-NK cells” NCT07589517 ↗ |